Evidence map›Paper›PMID 39962850›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2024

[Research Progress of Pulmonary Extranodal Marginal Zone Lymphoma].

Shaowei Zhang

Abstract readReviewEnglish Abstract
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Shaowei ZhangDepartment of Cardiothoracic Surgery, Pingdingshan Medical District, 989th Hospital of Joint Logistics Support Force, 
Pingdingshan 467021, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mucosa-associated lymphoid tissue (MALT) lymphoma is the most common primary pulmonary lymphoma, which is an indolent B-cell lymphoma thought to originate from marginal zone B cells. Its pathophysiology is closely related to chronic antigenic stimulation, regardless of whether the antigens are auto-antigens or of microbial origin. Due to its nonspecific clinical presentation and low prevalence, pulmonary MALT lymphoma is often misdiagnosed. The disease is slow-growing, and different treatments have shown good efficacy, but its optimal treatment is somewhat controversial. This paper reviews the epidemiology, pathogenesis, clinical manifestations, computed tomography (CT) features, pathological diagnosis, treatment and prognosis of pulmonary MALT lymphoma, providing reference for clinicians to further understanding of the disease.
.

Indexed as

Lung NeoplasmsLymphoma, B-Cell, Marginal ZoneHumansPrognosisTomography, X-Ray ComputedAnti-bacterial agentsMucosa-associated lymphoid tissue lymphomaNF-κB signal pathwayPrimary pulmonary lymphomaRituximab

Identifiers

PMID39962850
PMCPMC11839501

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.